Indeed, as per the 2024 EAU – EANM – ESTRO – ESUR – SIOG Guidelines on Prostate Cancer, 68Ga-PSMA PET/CT is not yet recommended as imaging modality for therapeutic assessment in clinical practice. This evidence concerns the gene FOLH1 and prostate carcinoma.